<DOC>
	<DOCNO>NCT02311101</DOCNO>
	<brief_summary>The study aim establish safety toxicity combine intravesical mitomycin C BCG patient bladder cancer .</brief_summary>
	<brief_title>Phase I Mitomycin Combined With Bacillus Calmette-Guérin ( BCG ) Bladder Cancer</brief_title>
	<detailed_description>Urine Sample Collection Handling : Voided urine collect pre post BCG procedure . Urinalysis perform participant present urinary symptom . Analysis urinary cytokine predictor response therapy conduct ELISA kit . Tissue Sample Collection Handling : Tissue biopsy specimen collect pre BCG procedure . Analysis gene expression conduct . TEST PROCEDURES Subjects give one three concentration Mitomycin C ( MMC ) ( 10 mg 20 mL , 20 mg 20 ml 40 mg 20 ml ) 30 minute follow 10 minute washout period . Followed three concentration BCG include ¼ strength , ½ strength , full strength 2 hour . Dose escalation take place among subsequent patient within patient . Approximately 30 subject enrol reach target completion enrollment 10 subject . Long-term Follow-up A Chart review conduct every three month 2 year initial 6 month study data collection . Patient chart review assess disease progression data support finding . Long-term follow-up necessary determine recurrence rate long-term safety efficacy Mitomycin/BCG treatment therapy well BCG therapy control group .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>1 . Newly diagnose recurrent multifocal Ta , large Ta , highgrade Ta , CIS , T1 bladder cancer 2 . In urologist 's opinion good candidate BCG induction therapy 3 . Be able give inform consent 4 . Be age 18 old . 1 . Inadequate marrow function ( define granulocytes less 1,500 cells/mm3 platelet le 150,000 cells/mm3 ) 2 . Immunosuppressed state ( e.g . HIV , use chronic steroid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>mitomycin</keyword>
	<keyword>BCG</keyword>
	<keyword>intravesical</keyword>
	<keyword>non-muscle invasive</keyword>
</DOC>